Your microbiome is measurable. It’s an ecosystem, after all—and like any ecosystem, you can observe how it responds to what you feed it. One way to do this is by observing the actual outputs of your gut bacteria: what they produce, how quickly they respond, and which microbial pathways are activated.
For us, understanding this relationship isn’t optional, but baseline. We’re not interested in developing and delivering a product based solely on assumptions or borrowing claims from generic fiber research. The goal is to see, as directly as possible, what our formulation is doing inside the gut—and whether it’s behaving the way we designed it to. And you deserve to know that the product you’re taking every day actually delivers on what it promises… with receipts.
That means testing LOAM in controlled environments with real human microbiota, measuring fermentation dynamics, and looking closely at the metabolites that are produced. Our first preclinical study has been completed.
Let’s take a closer look at what we found.
LOAM was shown to start working within 6 hours.†
We designed LOAM to be immediately bioavailable to your gut bacteria. Our preclinical study validated this: Specifically, showing that LOAM fueled the short chain fatty acid (SCFA) acetate, driving fermentation within 6 hours of use.
Acetate is the most abundant SCFA, with links to enhanced metabolic function, appetite control, and energy levels. This rapid fermentation is one of the clearest signals we observed regarding how quickly the microbiome responds to LOAM. Our gut microbes are engaging with it—and producing beneficial compounds like acetate—within hours.
LOAM fuels propionate production within 24-48 hours—at 2x more than inulin.†
We also looked more closely at propionate: a short chain fatty acid that’s less commonly discussed, but is a powerhouse for your health. Propionate is involved in cholesterol regulation in the liver, appetite signaling (via GLP-1 and PYY), and promoting broader metabolic health pathways.
In our data, we saw statistically significant increases in propionate at 24 and 48 hours. And to better understand this effect, we compared LOAM directly to inulin, one of the most widely used prebiotic fibers in foods and supplements. LOAM produced nearly 2x more propionate than inulin in both healthy and dysbiotic microbiomes.
LOAM fuels butyrate production within 24-48 hours.†
As fermentation continued, we also observed increases in butyrate. Butyrate is one of the most well-studied SCFAs, known for its role in supporting gut lining integrity, regulating inflammation in the colon, and serving as a primary energy source for colon cells.
Together, this sustained fermentation of multiple SCFAs points to diverse prebiotic activity driven by LOAM. In other words, we know that not all fibers are created equal—and our diverse formulation drives diverse fermentation.
LOAM was shown to produce significantly less gas.†
Bloating and discomfort are common side effects of fiber supplements, which informed our formulation of LOAM:
-
We specifically chose gentle, plant-based fibers that are low-FODMAP
-
We specifically developed a fiber profile with different fermentation speeds, so that LOAM wouldn’t ferment solely in the first part of the colon (which is often the culprit for gas and discomfort)
Our preclinical trials validated this approach. LOAM was shown to produce 21% less gas than inulin, which is a common fiber used in fiber supplements.
LOAM was shown to feed gut bacteria more efficiently.†
Interestingly, our findings didn’t just highlight the beneficial SCFAs LOAM helped produce—they also showed that LOAM reduced the production of toxic byproducts of protein fermentation like ammonium and branch chain fatty acids.
This contributes to a healthier microbiome profile overall and shifts it towards fiber fermentation.
A note on our study design
For our preclinical trials, we tested LOAM with an independent lab partner—which also happens to be one of the world leading institutes in microbiome analysis and preclinical research—using real human gut microbiota using an advanced, clinically relevant model of the colon. Our human samples included both healthy individuals and those with ulcerative colitis (also known as a dysbiotic gut).†
In other words, this wasn't just a test of LOAM in a singular microbiome profile or an “ideal gut type.” It displayed consistency across different donors with different gut ecosystems.
In the age of sensationalist marketing claims and lofty promises, our M.O. is to do the work and deliver on the promise of a healthier microbiome. Because if a product is going to be part of your daily routine, you should know what it’s actually doing inside your body.
† Ex vivo findings using a validated colonic fermentation model with human stool samples. Shown in laboratory studies using human gut microbiota.
